Trial Profile
A study evaluating Ibrutinib treatment discontinuation patterns for Chronic Lymphocytic Leukemia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Dec 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 27 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology